

March 2022

THERAPEUTIC AREA	PRODUCT	INDICATION	SAMPLES	TECHNICAL PACKAGE	VALIDATION BATCH	DMF
Antiasthmatics, COPD and respiratory diseases	Olodaterol^P	COPD	√	√	√	Q1 2023
	Indacaterol acetate	Asthma	√	Q3 2022	Q4 2022	Q2 2023
	Revefenacin	COPD	√	√	√	Q3 2022
	Umeclidinium bromide	COPD	√	√	√	Q1 2023
Antiparkinson	Bensarazide	Parkinson's disease	√	√	Q3 2022	Q2 2023
Other disorders	Tafamidis meglumine	Transthyretin amyloidosis	√	√	√	Q3 2022

CEP = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular, these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.